Medicare AdvantageCoverageMedium impact
MA08.185, Datopotamab deruxtecan (Datroway®)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Nov 3, 2025
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.185 for Datopotamab deruxtecan (Datroway®) has been implemented, establishing coverage guidelines for this oncology medication. This is a new pharmacy policy that will affect billing and coverage determinations for this specific drug therapy.
Action Required
By November 3, 2025: Billing team must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Datopotamab deruxtecan (Datroway®). Update pharmacy billing protocols and inform oncology providers of any new requirements for this medication.